What is low-grade fibromyxoid sarcoma?
Low-grade fibromyxoid sarcoma (LGFMS) is a rare, slow-growing soft-tissue cancer. It develops from fibroblasts, the cells that make the fibrous framework of connective tissue.
The name describes what the tumour looks like under the microscope: a mixture of fibrous (collagen-rich) and myxoid (soft, gel-like) areas made of cells that look deceptively harmless. It is sometimes called Evans tumour, after the pathologist who first described it in 1987.
LGFMS is very rare. A Danish national study estimated an incidence of about 0.18 cases per million people each year (Maretty-Nielsen et al., 2013). It most often affects young and middle-aged adults, usually in their 20s to 40s, but it can occur in children.
Although it is called “low grade” and grows slowly, LGFMS is a true sarcoma. It can come back after surgery and can spread to the lungs, sometimes many years or even decades after the first operation (Evans, 2011). This is why complete surgery and long-term follow-up are so important.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Low-grade fibroblastic soft-tissue sarcoma |
| How common | Very rare; under 1 case per million people per year |
| Typical age | Mostly 20-50 years; children can be affected |
| Common sites | Deep soft tissues of the thigh, shoulder, trunk and groin |
| Key symptom | A slowly enlarging, usually painless lump |
| Key test | Biopsy showing MUC4-positive cells and a FUS::CREB3L2 fusion |
| Main treatment | Wide surgical removal; radiotherapy in selected cases |
| Special feature | Late recurrence and lung spread can occur many years later |
| Outlook | Good survival in the first decade; long-term follow-up needed |
2. Causes and genetics
The cause of LGFMS is not known. It is not inherited and is not linked with lifestyle factors.
Most tumours carry a characteristic gene change created when two chromosomes swap pieces, called a translocation.
| Gene change | How often | Notes |
|---|---|---|
| FUS::CREB3L2 | About 90% | Created by t(7;16); highly specific for LGFMS (Panagopoulos et al., 2004) |
| FUS::CREB3L1 | Uncommon | Similar behaviour |
| EWSR1::CREB3L1 | Rare | More often seen in sclerosing epithelioid fibrosarcoma |
These changes are found only in the tumour cells. They are useful for diagnosis but cannot be passed on to children.
Related tumours
| Tumour | Relationship |
|---|---|
| Hyalinising spindle cell tumour with giant rosettes | A variant of LGFMS with rosette-like collagen structures (Lane, Shannon and Weiss, 1997) |
| Sclerosing epithelioid fibrosarcoma (SEF) | A related, more aggressive sarcoma; hybrid LGFMS-SEF tumours exist |
3. How does it look
On the body
| Feature | Description |
|---|---|
| Lump | Firm, rubbery, usually painless and slowly growing |
| Depth | Usually deep, below the fascia (the tough layer covering muscles) |
| Size | Often 5-10 cm by the time it is found, because it grows slowly |
| Skin | Normal over the lump |
| Location | Thigh, buttock, shoulder, chest wall, armpit, groin; occasionally the abdomen or head and neck |
On scans
MRI usually shows a well-defined mass in the deep soft tissues. Fibrous areas look dark and myxoid areas look bright on some sequences, giving a mixed or layered appearance. A CT of the chest looks for spread to the lungs.
Under the microscope
| Feature | Description |
|---|---|
| Cells | Bland, spindle-shaped cells with little variation in shape |
| Pattern | Alternating fibrous and myxoid zones; swirling (whorled) arrangement |
| Blood vessels | Arcades of small curving vessels in the myxoid areas |
| Collagen rosettes | Present in some tumours |
| Key stain | MUC4 positive in almost all cases (Doyle et al., 2011) |
| Dividing cells | Few; necrosis is unusual |
Because the cells look so harmless, LGFMS was often mistaken for a benign tumour in the past. Diagnosis by an expert sarcoma pathologist is recommended.
4. Symptoms
Common symptoms
- A lump deep in the thigh, shoulder, trunk or groin
- Gradual growth over months or years
- Usually no pain, although a large lump may ache
- Discomfort or stiffness if the lump presses on muscles or joints
- Numbness or tingling if it presses on a nerve (uncommon)
Symptoms depending on site
| Site | Possible symptoms |
|---|---|
| Abdomen or pelvis | Tummy fullness, discomfort, changes in bowel or bladder habit |
| Chest wall | A lump or ache in the chest |
| Head and neck | A visible lump; rarely difficulty swallowing |
Symptoms of spread
| Site | Possible symptoms |
|---|---|
| Lungs | Usually none at first; later cough, breathlessness or chest pain |
| Pleura (lung lining) | Fluid around the lung causing breathlessness |
| Bone or other organs | Pain at the site (rare) |
When to seek medical advice
See a doctor about any soft-tissue lump that is bigger than about 5 cm, getting bigger, deep in the muscle, or painful. These features need an urgent scan, ideally at a sarcoma centre.
5. Diagnosis
| Test | Purpose |
|---|---|
| Ultrasound | Often the first test for a lump |
| MRI | Shows the size, depth and relation to nerves, vessels and bone |
| Core needle biopsy | Samples tissue for diagnosis; done at or planned by a sarcoma centre |
| MUC4 staining | Highly sensitive and specific for LGFMS |
| FISH or sequencing | Detects FUS or EWSR1 rearrangements |
| CT of the chest | Looks for lung spread |
The biopsy should be planned with the sarcoma surgeon, so that the biopsy track can be removed during the later operation.
Conditions that can look similar
| Condition | How it differs |
|---|---|
| Desmoid tumour | Beta-catenin positive; does not spread |
| Myxofibrosarcoma | Usually older adults; more variable, atypical cells; MUC4-negative |
| Neurofibroma or perineurioma | Benign nerve-sheath tumours with different stains |
| Myxoma | Benign; GNAS changes in intramuscular myxoma |
| Sclerosing epithelioid fibrosarcoma | Related, more aggressive; epithelioid cells in dense collagen |
6. Treatment
People with LGFMS should be treated by a specialist sarcoma team, following guidelines such as those of ESMO (Gronchi et al., 2021).
Surgery
The main treatment is wide local excision: removing the tumour with a margin of healthy tissue all around it.
| Situation | Approach |
|---|---|
| Removable tumour | Wide excision with clear margins |
| Incomplete earlier removal (“whoops” excision) | Re-excision of the scar area to achieve clear margins |
| Tumour near nerves or vessels | Careful planning to preserve function; sometimes radiotherapy is added |
| Local recurrence | Further surgery whenever possible |
| Lung metastases | Surgical removal of lung nodules in selected patients (Maretty-Nielsen et al., 2013) |
Amputation is very rarely needed.
The first operation gives the best chance of cure. When a sarcoma is removed without planning, for example because it was thought to be a harmless lump, cells are often left behind and a second, larger operation is needed. This is why any deep or growing lump should be scanned and, if suspicious, referred to a sarcoma centre before surgery.
Radiotherapy
Radiotherapy may be used before or after surgery when the tumour is large, deep or close to vital structures, or when margins are close. It reduces the risk of the tumour returning locally.
Chemotherapy and other drugs
LGFMS grows slowly and generally responds poorly to chemotherapy. Chemotherapy is not routine but may be considered for widespread disease that is growing and causing symptoms.
| Option | Notes |
|---|---|
| Doxorubicin-based chemotherapy | Limited responses |
| Trabectedin, pazopanib | Used in some cases of advanced sarcoma |
| Observation | Often appropriate for small, stable lung nodules |
| Clinical trials | Recommended for advanced disease |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Before surgery | MRI and chest CT, a planned biopsy and a meeting with the sarcoma team |
| Radiotherapy before surgery (if used) | Daily treatments on weekdays for about 5 weeks, then surgery a few weeks later |
| Surgery | Usually a few days in hospital, longer for large or complex operations |
| Reconstruction | Sometimes a skin graft or tissue flap to close the wound |
| Rehabilitation | Physiotherapy to restore movement and strength, often for several months |
| Return to work | Often within weeks to a few months, depending on the site and type of job |
Most people with LGFMS are treated with surgery alone and can return to normal activities once the wound has healed.
LGFMS in children and teenagers
LGFMS can occur in children and adolescents. Treatment follows the same principles: complete surgical removal, avoiding radiotherapy where possible because of its effects on growing tissues. Children are usually treated at a children’s sarcoma centre within protocols for non-rhabdomyosarcoma soft-tissue sarcomas.
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery | Wound healing problems, scarring, weakness or stiffness; physiotherapy helps recovery |
| Radiotherapy | Skin redness, tiredness, wound problems, long-term stiffness or swelling (lymphoedema) |
| Chemotherapy | Tiredness, hair loss, sickness, infections |
7. Outlook (prognosis)
The outlook depends on complete removal and the length of follow-up.
| Measure | What studies show |
|---|---|
| Short to medium follow-up (73 patients) | Few recurrences or metastases within about 3-4 years (Folpe et al., 2000) |
| Long-term follow-up (33 patients, median about 14 years) | Recurrence in about 64%, metastasis in about 45%, death from disease in about 42% (Evans, 2011) |
| Timing of spread | Metastasis often appears 5-15 years or more after diagnosis |
| After complete removal | Better local control, though long-term surveillance is still needed |
The Evans series included many people treated before modern sarcoma surgery, so these figures may overestimate the risk for people treated today. Still, they show why LGFMS should never be regarded as a benign tumour.
Even when the tumour spreads to the lungs, it usually grows slowly, and many people live for years with treatment.
Why can it come back so late?
LGFMS cells divide very slowly. Small groups of cells left behind at the operation site, or that have already travelled to the lungs, can take many years to grow large enough to be noticed. This slow growth is also why chemotherapy, which works best on fast-dividing cells, is usually not very effective.
8. Follow-up
| Follow-up | Purpose |
|---|---|
| Clinical examination | Checks the operation site for new lumps |
| MRI of the original site | Detects local recurrence |
| Chest CT or X-ray | Detects lung metastases |
| Physiotherapy reviews | Supports recovery of strength and movement |
Follow-up is usually every 3-6 months for the first few years and then less often, but it should continue for at least 10 years, and many experts recommend lifelong checks because of late spread.
9. Living with LGFMS
- Keep attending follow-up, even many years after treatment
- Report new lumps at or near the scar
- Report persistent cough or breathlessness
- Do your physiotherapy exercises to regain strength and movement
- Ask about lymphoedema care if your limb swells after radiotherapy
- Contact a sarcoma charity for information and peer support
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is LGFMS cancer? | Yes. It is a low-grade sarcoma, a type of cancer |
| Why was I told it looked benign? | The cells look bland; expert review and MUC4 testing are needed |
| Can it spread? | Yes, mainly to the lungs, often years later |
| Do I need chemotherapy? | Usually not; surgery is the main treatment |
| How long will I need check-ups? | At least 10 years, and often lifelong |
| Is it inherited? | No. The gene change is only in the tumour |
| Can I exercise after treatment? | Yes. Exercise and physiotherapy help recovery; your team will advise when to start |
| Will the scar area always feel different? | Some firmness, numbness or tightness is common and often improves over months |
| Can children get it? | Yes, though it is more common in adults |
11. Questions to ask your care team
- Was the tumour removed with clear margins?
- Do I need radiotherapy?
- Has the diagnosis been confirmed with MUC4 or genetic testing?
- How often will I need scans, and for how long?
- What should I do if I notice a new lump?
- Are there clinical trials if the tumour comes back?
Resources
- Doyle, L.A. et al. (2011) ‘MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma’, American Journal of Surgical Pathology, 35(5), pp. 733-741.
- Evans, H.L. (2011) ‘Low-grade fibromyxoid sarcoma: a clinicopathologic study of 33 cases with long-term follow-up’, American Journal of Surgical Pathology, 35(10), pp. 1450-1462.
- Folpe, A.L. et al. (2000) ‘Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes: a clinicopathologic study of 73 cases supporting their identity and assessing the impact of high-grade areas’, American Journal of Surgical Pathology, 24(10), pp. 1353-1360.
- Gronchi, A. et al. (2021) ‘Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 32(11), pp. 1348-1365.
- Lane, K.L., Shannon, R.J. and Weiss, S.W. (1997) ‘Hyalinizing spindle cell tumor with giant rosettes: a distinctive tumor closely resembling low-grade fibromyxoid sarcoma’, American Journal of Surgical Pathology, 21(12), pp. 1481-1488.
- Maretty-Nielsen, K. et al. (2013) ‘Low-grade fibromyxoid sarcoma: incidence, treatment strategy of metastases, and clinical significance of the FUS gene’, Sarcoma, 2013, 256280.
- Mohamed, M., Fisher, C. and Thway, K. (2017) ‘Low-grade fibromyxoid sarcoma: clinical, morphologic and genetic features’, Annals of Diagnostic Pathology, 28, pp. 60-67.
- Panagopoulos, I. et al. (2004) ‘The chimeric FUS/CREB3l2 gene is specific for low-grade fibromyxoid sarcoma’, Genes, Chromosomes and Cancer, 40(3), pp. 218-228.
- National Cancer Institute (2026) Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.